Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2526479> ?p ?o }
Showing triples 1 to 66 of
66
with 100 triples per page.
- Q2526479 subject Q7214357.
- Q2526479 subject Q7403984.
- Q2526479 subject Q8255706.
- Q2526479 subject Q8256381.
- Q2526479 subject Q8821816.
- Q2526479 abstract "Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.The product was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010. More recently, Liraglutide was approved by the FDA on December 23, 2014 for treatment for obesity in adults with some related comorbidity.".
- Q2526479 thumbnail Liraglutide.png?width=300.
- Q2526479 wikiPageWikiLink Q1029907.
- Q2526479 wikiPageWikiLink Q1057.
- Q2526479 wikiPageWikiLink Q11364.
- Q2526479 wikiPageWikiLink Q1164665.
- Q2526479 wikiPageWikiLink Q12174.
- Q2526479 wikiPageWikiLink Q130146.
- Q2526479 wikiPageWikiLink Q1414874.
- Q2526479 wikiPageWikiLink Q1420402.
- Q2526479 wikiPageWikiLink Q14599311.
- Q2526479 wikiPageWikiLink Q14821391.
- Q2526479 wikiPageWikiLink Q14904803.
- Q2526479 wikiPageWikiLink Q14911850.
- Q2526479 wikiPageWikiLink Q1527888.
- Q2526479 wikiPageWikiLink Q169219.
- Q2526479 wikiPageWikiLink Q1767180.
- Q2526479 wikiPageWikiLink Q186319.
- Q2526479 wikiPageWikiLink Q202758.
- Q2526479 wikiPageWikiLink Q204711.
- Q2526479 wikiPageWikiLink Q21163221.
- Q2526479 wikiPageWikiLink Q212410.
- Q2526479 wikiPageWikiLink Q219508.
- Q2526479 wikiPageWikiLink Q245359.
- Q2526479 wikiPageWikiLink Q271993.
- Q2526479 wikiPageWikiLink Q275157.
- Q2526479 wikiPageWikiLink Q285982.
- Q2526479 wikiPageWikiLink Q3025883.
- Q2526479 wikiPageWikiLink Q37525.
- Q2526479 wikiPageWikiLink Q380418.
- Q2526479 wikiPageWikiLink Q417762.
- Q2526479 wikiPageWikiLink Q419770.
- Q2526479 wikiPageWikiLink Q424611.
- Q2526479 wikiPageWikiLink Q425027.
- Q2526479 wikiPageWikiLink Q4712362.
- Q2526479 wikiPageWikiLink Q47270.
- Q2526479 wikiPageWikiLink Q4810139.
- Q2526479 wikiPageWikiLink Q5572286.
- Q2526479 wikiPageWikiLink Q61424.
- Q2526479 wikiPageWikiLink Q61476.
- Q2526479 wikiPageWikiLink Q7214357.
- Q2526479 wikiPageWikiLink Q7257343.
- Q2526479 wikiPageWikiLink Q7403984.
- Q2526479 wikiPageWikiLink Q7687607.
- Q2526479 wikiPageWikiLink Q79749.
- Q2526479 wikiPageWikiLink Q8047.
- Q2526479 wikiPageWikiLink Q818846.
- Q2526479 wikiPageWikiLink Q8255706.
- Q2526479 wikiPageWikiLink Q8256381.
- Q2526479 wikiPageWikiLink Q826522.
- Q2526479 wikiPageWikiLink Q8821816.
- Q2526479 wikiPageWikiLink Q9377.
- Q2526479 wikiPageWikiLink Q9618.
- Q2526479 type ChemicalSubstance.
- Q2526479 type Drug.
- Q2526479 type ChemicalObject.
- Q2526479 type Thing.
- Q2526479 type Q8386.
- Q2526479 comment "Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S.".
- Q2526479 label "Liraglutide".
- Q2526479 depiction Liraglutide.png.